Crossmark

miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection

Crossref DOI link: https://doi.org/10.1038/s41598-025-15248-6

Published Online: 2025-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mustafa, Farah https://orcid.org/0000-0002-1081-3756
Ahmad, Waqar https://orcid.org/0000-0003-0474-6558
Gull, Bushra https://orcid.org/0000-0003-0383-3908
Baby, Jasmin https://orcid.org/0000-0001-5563-9846
Panicker, Neena G. https://orcid.org/0000-0002-7553-9006
Khader, Thanumol Abdul https://orcid.org/0000-0002-1338-2568
Baki, Hala Abdul https://orcid.org/0000-0002-7071-7387
Rehman, Erum

Salim, Asif M. https://orcid.org/0009-0003-0301-8265
Ahmed, Rubina L. G.

Khansaheb, Hamda H. https://orcid.org/0000-0002-7129-1138
Habous, Maya

AlDabal, Laila M. J. A.

Jaballah, Soumeya https://orcid.org/0009-0000-6269-9759
Alqassim, Saif S. https://orcid.org/0000-0002-1726-1587
Alsheikh-Ali, Alawi

Rizvi, Tahir A. https://orcid.org/0000-0002-2572-1678
Funding

Funding for this research was provided by:

Al Jalila Foundation (AJF2020006)

ASPIRE Grant (AARE20-344)

ATRC (VRI-20-10)
License Information

Text and Data Mining valid from 2025-08-21

Version of Record valid from 2025-08-21
More Information

Article History

Received: 26 February 2025

Accepted: 6 August 2025

First Online: 21 August 2025

Declarations

:

: The authors declare no competing interests.

: The study was approved by the UAE University (UAEU) Human Research Ethics Committee (HREC approval no: ERH-2020-7219 2020-22) and the Dubai Scientific Research Ethics Committee (DSREC) of the Dubai Health Authority (DHA) (DSREC approval nos: DSREC-11/2020_16 and DSREC-11/2021_08). Consent was taken from each subject following DHA and UAEU established procedures.

: All authors read and approved the final manuscript.

Document is current

Any future updates will be listed below